OUR PRODUCTS

Our Pipeline

We challenge ourselves to rethink the way medicines are developed,
and are investing now to bring more value to patients in the future.

We strive for constant innovation and we are putting our passion and expertise to work in new areas including ophthalmology, gastroenterology, and hematology.

SB8

Biosimilar candidate

  • Molecule Bevacizumab
  • Reference Biologic Avastin®i
  • Therapeutic Area Oncology
SB11

Biosimilar candidate

  • Molecule Ranibizumab
  • Reference Biologic Lucentis®ii
  • Therapeutic Area Ophthalmology
SB12

Biosimilar candidate

  • Molecule Eculizumab
  • Reference Biologic Soliris®iii
  • Therapeutic Area Hematology
SB26

Novel biologic

  • Molecule Ulinastatin-Fc
    Fusion Protein
  • Therapeutic Area Gastroenterology

*Pipeline last updated Jul 2019

  • iAvastin® is a registered trademark of Genentech
  • iiLucentis® is a registered trademark of Genentech
  • iiiSoliris® is a registered trademark of Alexion
SAMSUNG BIOEPIS

You are now leaving the Samsung Bioepis website.
Samsung Bioepis provides this link as a courtesy and does not control the content of the site you are about to enter into. Do you wish to continue?

확인 취소
레이어 팝업 닫기